Search for content, post, videos

Recipharm acquires Arranta Bio and Vibalogics

Recipharm has announced the acquisition of Arranta Bio, an advanced therapy CDMO, and Vibalogics, a virotherapy CDMO and a portfolio company of Ampersand Capital Partners. The acquisition of Arranta Bio forms a cornerstone of Recipharm’s strategy to provide innovative drug developers in the bio
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.